ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Routine meningococcal vaccination recommendations for healthy adolescents and young adults age 11 through 23 years in the United States[1-3]

Routine meningococcal vaccination recommendations for healthy adolescents and young adults age 11 through 23 years in the United States[1-3]
Meningococcal vaccine Primary dose(s) Booster dose(s)
MenACWY
(for those age 11 through 21 years)*		 MenACWY (any licensed vaccine):
  • 1 dose, at age 11 through 18 years; preferred age: 11 through 12 years
 MenACWY (any licensed vaccine):
  • 1 dose at age ≥16 years; the minimum interval between doses is 8 weeks.
  • If first dose given after age 16 years, then booster is not needed unless the person is at increased risk for meningococcal disease.
  • College freshmen living in residence halls should receive ≥1 dose of MenACWY ≤5 years before college entry.
MenB
(for those age 16 through 23 years based on shared decision-making)Δ		 Preferred age: 16 through 18 years

Either:

  • MenB-4C: 2 doses, ≥1 month apart
  • or
  • MenB-FHbp: 2 doses, ≥6 months apart
 Not routinely recommended unless the person becomes at risk (eg, exposed during an outbreak, occupational risk).
This table is meant for use with UpToDate content on meningococcal vaccination. Refer to UpToDate content for additional details, including meningococcal vaccination of persons at increased risk of meningococcal disease and details of shared decision-making.
  • Two MenACWY are licensed in the United States:
    • MenACWY-CRM (Menveo)
    • MenACWY-TT (MenQuadfi)
  • MenACWY-D (Menactra) was discontinued in 2022.
  • Although each of the MenACWY vaccine formulations use a different protein conjugate, the products are considered interchangeable in persons ≥2 years of age. The same vaccine product is recommended, but not required, for all doses.
  • Two MenB vaccines are licensed in the United States:
    • MenB-4C (Bexsero)
    • MenB-FHbp (Trumenba)
  • MenB vaccines are not interchangeable; the same brand must be used for each dose of the primary series and all booster doses (if indicated).

MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenB: serogroup B meningococcal vaccine; ACIP: Advisory Committee on Immunization Practices.

* Although the ACIP recommends routine MenACWY vaccination only for adolescents age 11 through 18 years, MenACWY may be given to persons age 19 through 21 years who have not received a dose.

¶ For unvaccinated adolescents and young adults with an underlying condition for which a 2-dose primary series of MenACWY vaccination is recommended, the second dose should be given as soon after the 8-week minimum interval as possible.

Δ Given the seriousness of meningococcal disease and efficacy and safety of available formulations, we suggest MenB for persons age 16 through 23 years.
References:
  1. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.
  2. Immunization Action Coalition. Meningococcal ACWY vaccine recommendations by age and risk factor. https://www.immunize.org/catg.d/p2018.pdf (Accessed on October 26, 2020).
  3. Immunization Action Coalition. Meningococcal B vaccine recommendations by age and risk factor. https://www.immunize.org/catg.d/p2035.pdf (Accessed on October 26, 2020).
Graphic 130148 Version 3.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟